Dysregulated MicroRNA Expression Profiles and Potential Cellular, Circulating and Polymorphic Biomarkers in Non-Hodgkin Lymphoma

Overview

Journal Genes (Basel)

Publisher MDPI

Date 2016 Dec 22

PMID 27999330

Citations 11

Authors

Gabrielle Bradshaw

Heidi G Sutherland

Larisa M Haupt

Lyn R Griffiths

Affiliations

Soon will be listed here.

Abstract

A large number of studies have focused on identifying molecular biomarkers, including microRNAs (miRNAs) to aid in the diagnosis and prognosis of the most common subtypes of non-Hodgkin lymphoma (NHL), Diffuse Large B-cell Lymphoma and Follicular Lymphoma. NHL is difficult to diagnose and treat with many cases becoming resistant to chemotherapy, hence the need to identify improved biomarkers to aid in both diagnosis and treatment modalities. This review summarises more recent research on the dysregulated miRNA expression profiles found in NHL, as well as the regulatory role and biomarker potential of cellular and circulating miRNAs found in tissue and serum, respectively. In addition, the emerging field of research focusing on miRNA single nucleotide polymorphisms (miRSNPs) in genes of the miRNA biogenesis pathway, in miRNA genes themselves, and in their target sites may provide new insights on gene expression changes in these genes. These miRSNPs may impact miRNA networks and have been shown to play a role in a host of different cancer types including haematological malignancies. With respect to NHL, a number of SNPs in miRNA-binding sites in target genes have been shown to be associated with overall survival.

Citing Articles

The Roles of Exosomal microRNAs in Diffuse Large B-Cell Lymphoma: Diagnosis, Prognosis, Clinical Application, and Biomolecular Mechanisms.

Yazdanparast S, Huang Z, Keramat S, Izadirad M, Li Y, Bo L Front Oncol. 2022; 12:904637.

PMID: 35719983 PMC: 9202611. DOI: 10.3389/fonc.2022.904637.

Epigenetic Regulation of miR-92a and TET2 and Their Association in Non-Hodgkin Lymphoma.

Elliott E, Hopkins L, Hensen R, Sutherland H, Haupt L, Griffiths L Front Genet. 2021; 12:768913.

PMID: 34899857 PMC: 8661906. DOI: 10.3389/fgene.2021.768913.

MicroRNA and Other Non-Coding RNAs in Epstein-Barr Virus-Associated Cancers.

Notarte K, Senanayake S, Macaranas I, Albano P, Mundo L, Fennell E Cancers (Basel). 2021; 13(15).

PMID: 34359809 PMC: 8345394. DOI: 10.3390/cancers13153909.

The Multifaceted Role and Utility of MicroRNAs in Indolent B-Cell Non-Hodgkin Lymphomas.

Artemaki P, Letsos P, Zoupa I, Katsaraki K, Karousi P, Papageorgiou S Biomedicines. 2021; 9(4).

PMID: 33806113 PMC: 8064455. DOI: 10.3390/biomedicines9040333.

Regulatory Mechanisms of Epigenetic miRNA Relationships in Human Cancer and Potential as Therapeutic Targets.

Arif K, Elliott E, Haupt L, Griffiths L Cancers (Basel). 2020; 12(10).

PMID: 33050637 PMC: 7600069. DOI: 10.3390/cancers12102922.

References

Cipollini M, Landi S, Gemignani F . MicroRNA binding site polymorphisms as biomarkers in cancer management and research. Pharmgenomics Pers Med. 2014; 7:173-91. PMC: 4126202. DOI: 10.2147/PGPM.S61693. View

Zhang Y, Takahashi S, Tasaka A, Yoshima T, Ochi H, Chayama K . Involvement of microRNA-224 in cell proliferation, migration, invasion, and anti-apoptosis in hepatocellular carcinoma. J Gastroenterol Hepatol. 2012; 28(3):565-75. DOI: 10.1111/j.1440-1746.2012.07271.x. View

Diao L, Su H, Wei G, Li T, Gao Y, Zhao G . Prognostic value of microRNA 502 binding site SNP in the 3'-untranslated region of the SET8 gene in patients with non-Hodgkin's lymphoma. Tumori. 2014; 100(5):553-8. DOI: 10.1700/1660.18180. View

Li T, Niu L, Wu L, Gao X, Li M, Liu W . A functional polymorphism in microRNA-196a2 is associated with increased susceptibility to non-Hodgkin lymphoma. Tumour Biol. 2014; 36(5):3279-84. DOI: 10.1007/s13277-014-2957-y. View

Hans C, Weisenburger D, Greiner T, Gascoyne R, Delabie J, Ott G . Confirmation of the molecular classification of diffuse large B-cell lymphoma by immunohistochemistry using a tissue microarray. Blood. 2003; 103(1):275-82. DOI: 10.1182/blood-2003-05-1545. View

Bai H, Wei J, Deng C, Yang X, Wang C, Xu R . MicroRNA-21 regulates the sensitivity of diffuse large B-cell lymphoma cells to the CHOP chemotherapy regimen. Int J Hematol. 2013; 97(2):223-31. DOI: 10.1007/s12185-012-1256-x. View

Yang B, Liu C, Diao L, Wang C, Guo Z . A polymorphism at the microRNA binding site in the 3' untranslated region of C14orf101 is associated with non-Hodgkin lymphoma overall survival. Cancer Genet. 2014; 207(4):141-6. DOI: 10.1016/j.cancergen.2014.03.007. View

Culpin R, Proctor S, Angus B, Crosier S, Anderson J, Mainou-Fowler T . A 9 series microRNA signature differentiates between germinal centre and activated B-cell-like diffuse large B-cell lymphoma cell lines. Int J Oncol. 2010; 37(2):367-76. DOI: 10.3892/ijo_00000685. View

Feugier P, Van Hoof A, Sebban C, Solal-Celigny P, Bouabdallah R, Ferme C . Long-term results of the R-CHOP study in the treatment of elderly patients with diffuse large B-cell lymphoma: a study by the Groupe d'Etude des Lymphomes de l'Adulte. J Clin Oncol. 2005; 23(18):4117-26. DOI: 10.1200/JCO.2005.09.131. View

10.

Roehle A, Hoefig K, Repsilber D, Thorns C, Ziepert M, Wesche K . MicroRNA signatures characterize diffuse large B-cell lymphomas and follicular lymphomas. Br J Haematol. 2008; 142(5):732-44. DOI: 10.1111/j.1365-2141.2008.07237.x. View

11.

Rosenwald A, Wright G, Leroy K, Yu X, Gaulard P, Gascoyne R . Molecular diagnosis of primary mediastinal B cell lymphoma identifies a clinically favorable subgroup of diffuse large B cell lymphoma related to Hodgkin lymphoma. J Exp Med. 2003; 198(6):851-62. PMC: 2194208. DOI: 10.1084/jem.20031074. View

12.

Lim E, Trinh D, Scott D, Chu A, Krzywinski M, Zhao Y . Comprehensive miRNA sequence analysis reveals survival differences in diffuse large B-cell lymphoma patients. Genome Biol. 2015; 16:18. PMC: 4308918. DOI: 10.1186/s13059-014-0568-y. View

13.

Zhao C, Wang G, Zhu Y, Li X, Yan F, Zhang C . Aberrant regulation of miR-15b in human malignant tumors and its effects on the hallmarks of cancer. Tumour Biol. 2015; 37(1):177-83. DOI: 10.1007/s13277-015-4269-2. View

14.

Marques S, Ranjbar B, Laursen M, Falgreen S, Bilgrau A, Bodker J . High miR-34a expression improves response to doxorubicin in diffuse large B-cell lymphoma. Exp Hematol. 2016; 44(4):238-46.e2. DOI: 10.1016/j.exphem.2015.12.007. View

15.

Chakraborty C, Das S . Profiling cell-free and circulating miRNA: a clinical diagnostic tool for different cancers. Tumour Biol. 2016; 37(5):5705-14. DOI: 10.1007/s13277-016-4907-3. View

16.

Huang J, Shi Y, Li H, Yang M, Liu G . MicroRNA-144 acts as a tumor suppressor by targeting Rho-associated coiled-coil containing protein kinase 1 in osteosarcoma cells. Mol Med Rep. 2015; 12(3):4554-4559. DOI: 10.3892/mmr.2015.3937. View

17.

Rossi D, Berra E, Cerri M, Deambrogi C, Barbieri C, Franceschetti S . Aberrant somatic hypermutation in transformation of follicular lymphoma and chronic lymphocytic leukemia to diffuse large B-cell lymphoma. Haematologica. 2006; 91(10):1405-9. View

18.

Gao Y, Diao L, Li H, Guo Z . Single nucleotide polymorphisms of microRNA processing genes and outcome of non-Hodgkin's lymphoma. Onco Targets Ther. 2015; 8:1735-41. PMC: 4508071. DOI: 10.2147/OTT.S86338. View

19.

Leich E, Salaverria I, Bea S, Zettl A, Wright G, Moreno V . Follicular lymphomas with and without translocation t(14;18) differ in gene expression profiles and genetic alterations. Blood. 2009; 114(4):826-34. PMC: 2716022. DOI: 10.1182/blood-2009-01-198580. View

20.

Metzler M, Wilda M, Busch K, Viehmann S, Borkhardt A . High expression of precursor microRNA-155/BIC RNA in children with Burkitt lymphoma. Genes Chromosomes Cancer. 2003; 39(2):167-9. DOI: 10.1002/gcc.10316. View